Roche Diagnostics Korea (CEO Kit Tang) recently announced that ‘cobas EBV’ and ‘cobas BKV’, tests for virus and infection monitoring of organ transplant patients, have been approved as in vitro diagnostic medical devices. work said
All of these tests are available on the cobas 6800 and cobas 8800 systems, which are high-capacity automated molecular testing equipment.
Roche Diagnostics Korea said that by releasing the EBV and BKV tests following CMV4, it is possible not only to perform three simultaneous tests using a single sample, but also to help in early detection of viral overlapping infection.
By providing results according to WHO international standards, these tests can be followed up and can improve the concordance rate of results among laboratories and hospitals, he said.
The Covas EBV test is used to indicate the need for a potential treatment change in patients being monitored for Epstein-Barr Virus (EBV) and to evaluate the viral response to treatment.
The Kovas BKV test can help diagnose and manage the BK virus in organ transplant patients, and is tested using human EDTA plasma and urine.
Kit Tang, CEO of Roche Diagnostics Korea, said, “Through the launch of Kovas EBV and BKV, we will do our best to provide consistent and reliable results for infection control and treatment monitoring of transplant patients, as well as contribute to customized treatment and management for patients in the future. I will do it,” he said.
